Aim: To measure the frequency and severity of hepatotoxicity caused by various anti-tuberculosis (ATT) drugs and assess whether concurrence of risk factors impact the hepatotoxicity induced by anti-tuberculosis drug. Study Design:Prospective cohort study. Place and duration of study: Department of Medicine, Lady Reading Hospital, Peshawar from 1stMarch 2018 to 28th February 2019. Method: A total of 350 patients were observed who were identified with active tuberculosis infection with clinical and biochemical normal liver function. The data was collected and the patients were treated with Isoniazid, rifampicin and pyrazinamide. The time later to imbalance in function, if any, happened and time required for regularization was calculated. If necessary, the treatment was changed, except for the harmful drug. Results: Seventy one (20.3%) patients have ATT-induced hepatotoxicity. Women were more affected than men (27% vs. 20%). BMI (kg/m2) of 92% in the patient group, was less than 18.3 (p <0.01), many of them had anemia and suggested low albumin mass. In patients with positive AFB smear; there was more severe hepatotoxicity noted. Simultaneous use of low serum cholesterol, paracetamol and alcohol has been shown to be predisposing factors. The main culprit was isoniazid 40(56.3%) patients, p <0.01] charted by pyrazinamide 10(14.08%) and rifampicin 25(35.21%) patients. Many of the subjects included (61%) experienced mild to moderate hepatotoxicity with ALT and AST within 2 weeks of initial to treatment of tuberculosis. Conclusion: Anti-tuberculosis treatment persuaded hepatitis is very common and have much serious effects in cases with risk factors for hepatotoxicity.